BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Novo Nordisk (NVO) reported headline results from the main phases of ONWARDS 1 and ONWARDS 6 phase 3a trials with once-weekly insulin icodec. The ONWARDS 1 trial achieved primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 52 with insulin icodec compared to insulin glargine. The ONWARDS 6 trial achieved its primary endpoint of showing non-inferiority in reducing HbA1c at week 26 with insulin icodec compared to insulin degludec.
'The results of the main phase of ONWARDS 1 confirm the strong results seen in ONWARDS 2 and strengthen the profile of once-weekly insulin icodec which has the potential to become the ideal insulin for people with type 2 diabetes initiating insulin treatment', said Martin Holst Lange, executive vice president for Development at Novo Nordisk.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX